These observations lead to the unexpected notion that under conditions of activated bone remodeling like in response to PTH treatment (Fig 4C and E) but also upon ovariectomy (Fig 5H) as a model of sex steroid deficiency‐induced osteoporosis, but not under conditions of normal bone remodeling, the predominant effect of anti‐miR‐19a/b treatment on increasing bone mass is by attenuating the activated bone resorption. The gene discussed is PTH; the disease is osteoporosis.